Fanconi renotubular syndrome 3 (FRTS3): A Patient Guide
At a Glance
FRTS3 is a rare genetic kidney disorder in which the kidney’s recycling tubes lose phosphate and bicarbonate into urine. Because the gene change cannot currently be repaired, individualized supplements and regular blood and urine tests help protect bone and kidney health.
Fanconi renotubular syndrome 3 (FRTS3) is an exceptionally rare genetic condition that fundamentally changes how the kidneys manage the body’s essential nutrients. Because the evidence is limited to a very small number of reported families, treatment decisions must be highly individualized. Unlike many kidney diseases that involve a failure to filter the blood, FRTS3 is a disorder of the “recycling” system located in the proximal tubules [1][2].
In a healthy kidney, these tubules act as a sophisticated reclamation center, pulling vital substances like sugar, phosphate, and bicarbonate back into the bloodstream before they can be lost in the urine. In people with FRTS3, a pathogenic variant in the EHHADH gene disrupts the energy production within these tubule cells, leaving them without the power they need to perform this critical recycling work [3][4].
When this reclamation process fails, the body begins to “waste” essential building blocks into the urine. This loss of nutrients—particularly phosphate and bicarbonate—can lead to significant challenges for bone health and the body’s overall acid-base balance [5]. Over time, the chronic loss of phosphate may cause bones to soften or weaken, a condition known as rickets in children or osteomalacia in adults [2][6]. Because the kidneys are also losing water along with these nutrients, some individuals experience a constant, intense thirst and a frequent need to urinate [7].
One of the most striking features of FRTS3 is its profound variability. Even within the same family, where multiple people carry the exact same genetic variant, the condition can behave very differently [2]. One person might have severe symptoms that require several daily supplements, while a relative might have only minor lab abnormalities and no physical symptoms at all [4][8]. This unpredictability means that while some patients face earlier kidney impairment, others maintain stable health and good kidney function for many decades [2][9].
Because there is currently no way to repair the underlying genetic variant, management focuses on supportive care—the process of carefully replacing exactly what the kidneys are losing [10]. This journey requires a lifelong partnership with a specialized nephrology or metabolic-bone team. Regular blood and urine monitoring helps ensure the body’s mineral levels remain in a healthy range [11][12]. While living with a rare diagnosis brings unique challenges, a consistent, individualized management plan aims to reduce complications, protect bone health, and preserve kidney function [2].
In this guide
6 chapters
Understanding FRTS3: Biology and Genetics
Learn how Fanconi renotubular syndrome 3 affects proximal tubules, how EHHADH variants disrupt cell energy, and what autosomal dominant inheritance means.
Symptoms and Emergency Warning Signs
Learn the symptoms of Fanconi renotubular syndrome 3, including thirst, bone pain, dehydration, muscle weakness, and emergency signs needing urgent care.
Diagnosis and Distinguishing from Look-alikes
Learn how Fanconi renotubular syndrome 3 is diagnosed, including urine and blood tests, EHHADH genetic testing, and how doctors rule out look-alike conditions.
Specialist-Directed Supportive Treatment
Learn how FRTS3 supportive treatment replaces lost bicarbonate, phosphate, and potassium, supports bone health, and monitors urine calcium and kidney risks.
Day-to-Day Management and Monitoring
Learn how Fanconi renotubular syndrome 3 (FRTS3) is monitored with blood and urine tests, kidney and bone checks, and when monitoring may need to increase.
Prognosis and the Long-Term Outlook
Learn about Fanconi renotubular syndrome 3 prognosis, including variable symptoms, kidney function, lifelong monitoring, and ways to reduce complications.
Common questions in this guide
What is Fanconi renotubular syndrome 3 (FRTS3)?
What symptoms can FRTS3 cause?
How is FRTS3 diagnosed and monitored?
How is FRTS3 treated?
Does everyone with FRTS3 develop kidney failure?
Should family members be tested for FRTS3?
Get notified when new evidence is published on Fanconi renotubular syndrome 3.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Proximal renal tubular acidosis with and without Fanconi syndrome.
Kashoor I, Batlle D
Kidney research and clinical practice 2019; (38(3)):267-281 doi:10.23876/j.krcp.19.056.
PMID: 31474092 - 2
A puzzling renal Fanconi syndrome.
Haydock L, Hureaux M, Hoffmann M, et al.
Clinical kidney journal 2025; (18(8)):sfae408 doi:10.1093/ckj/sfae408.
PMID: 40800210 - 3
Renal Fanconi Syndrome Is Caused by a Mistargeting-Based Mitochondriopathy.
Assmann N, Dettmer K, Simbuerger JMB, et al.
Cell reports 2016; (15(7)):1423-1429 doi:10.1016/j.celrep.2016.04.037.
PMID: 27160910 - 4
The recurrent p.Glu3Lys variant in EHHADH is responsible for Fanconi syndrome with early liver dysfunction and mitochondrial abnormalities.
Rollier P, Cospain A, Barth M, et al.
Molecular genetics and metabolism reports 2025; (43()):101214 doi:10.1016/j.ymgmr.2025.101214.
PMID: 40242153 - 5
Fanconi Syndrome.
Foreman JW
Pediatric clinics of North America 2019; (66(1)):159-167 doi:10.1016/j.pcl.2018.09.002.
PMID: 30454741 - 6
[GENETIC DISORDERS OF RENAL PHOSPHATE HANDLING].
Magen D
Harefuah 2017; (156(10)):654-658.
PMID: 29072386 - 7
A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus.
Hoang S, Pujar T, Bellorin-Font E, et al.
CEN case reports 2024; (13(3)):194-198 doi:10.1007/s13730-023-00829-z.
PMID: 37897631 - 8
Unveiling long-standing low-molecular-weight proteinuria: A proximal tubular mitochondrial enzyme impairment caused by EHHADH mutation.
Tanaka H, Imasawa T, Tsugawa K, et al.
Pediatric nephrology (Berlin, Germany) 2026; (41(3)):675-678 doi:10.1007/s00467-025-07020-9.
PMID: 41117969 - 9
Inherited Fanconi renotubular syndromes: unveiling the intricacies of hypophosphatemic rickets/osteomalacia.
Ragate DC, Memon SS, Karlekar M, et al.
Journal of bone and mineral metabolism 2024; (42(2)):155-165 doi:10.1007/s00774-023-01490-3.
PMID: 38310177 - 10
Renal Tubular Acidosis.
Bagga A, Sinha A
Indian journal of pediatrics 2020; (87(9)):733-744 doi:10.1007/s12098-020-03318-8.
PMID: 32591997 - 11
Management of bone disease in cystinosis: Statement from an international conference.
Hohenfellner K, Rauch F, Ariceta G, et al.
Journal of inherited metabolic disease 2019; (42(5)):1019-1029 doi:10.1002/jimd.12134.
PMID: 31177550 - 12
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D
Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.
PMID: 35352187
This page is for informational purposes only and does not constitute medical advice. FRTS3 treatment is individualized, so discuss genetic testing, supplements, and monitoring with your nephrologist or metabolic-bone specialist.